Qiaojing Capital
VC Fund
Shanghai, China
Qiaojing Capital is an investment firm that invests in the medical, consumer & supply chain financial management industries. Qiao Jing Capital's core operation team has experience in senior management positions in well-known asset management companies at home and abroad. The company's operations fully follow the leading models athome and abroad, and pursue strict risk management and efficient incentive mechanisms.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Qiaojing Capital invests in
Stages Qiaojing Capital invests in
Countries Qiaojing Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.4M–$40M
- Series B
- $10M–$15M
- Post-IPO Equity
- $1.5M–$38M
Investment Focus
Industry
- Health Care 7 (35%)
- Medical 6 (30%)
- Medical Device 4 (20%)
- Manufacturing 3 (15%)
- Internet 2 (10%)
Stage
- Series A 8 (40%)
- Series B 4 (20%)
- Post-IPO Equity 3 (15%)
- Angel 2 (10%)
- Series C 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kim Min
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
|
Yu Zhe
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Zhu Haorong
Founding Partner
|
Founding Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Yisheng Microna is an ultrasonic transducer designer and developer, focusing on providing minimally invasive interventional ultrasonography catheters and transducers. | $6.3M / Series A / Mar 13, 2024 | ||
| Elite Technology is a company that specializes in the development of chromatographic techniques, workstations, and high-performance liquid chromatography equipment for analysis, preparation, and industrial production. | $14.1M / Angel / Jan 05, 2024 | ||
| Hicicare is a medical technology company that specializes in the development of pan-vascular interventional medical devices. | $14M / Series A / Dec 07, 2023 | ||
| Jianxin Bio focuses on new monoclonal antibody drugs, CAR-T (Chimeric Antigen Receptor T Cell) technology innovation. | Series B / Mar 20, 2023 | ||
Jinfang Pharmaceutical
|
Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies. | $77.1M / Series C / Dec 31, 2021 | |
| Leto Laboratories is a manufacturer of protein products. | $14.9M / Series B / Oct 16, 2020 | ||
| Wanxu Software is a Healthcare company. | $2.9M / Series A / Aug 21, 2018 | ||
| A Company Focused on Supply Chain Management of high value medical consumables. | $39.5M / Series A / Jan 30, 2018 | ||
| Zheng Heng is adistributor of diesel vehicle OEMs and products. They provide products that include cylinder blocks, cylinder heads, bearing caps, and gearbox housings. They provide services for electric vehicles. | $30.6M / Post-IPO Equity / Sep 05, 2017 | ||
| Hongjitang is a manufacturer of pediatric medicine, gynecological drugs, respiratory drugs, blood circulation pain relievers, neuro cancer drugs, genitourinary system drugs, and cardiovascular drugs. It also offers pills, powders, tablets, combinations, tinctures, gels, capsules, granules, decoctions, and oral liquids. | $37.8M / Post-IPO Equity / Mar 24, 2017 | ||
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Qiaojing Capital invest in?
Qiaojing Capital invests primarily in Health Care, Medical and Medical Device startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Qiaojing Capital's check size?
Qiaojing Capital typically joins rounds of $1.4M–$40M at Series A, $10M–$15M at Series B and $1.5M–$38M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Qiaojing Capital participates in.
How do I contact Qiaojing Capital?
Public channels for Qiaojing Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Qiaojing Capital?
The team at Qiaojing Capital includes Kim Min (Founding Partner), Yu Zhe (Managing Director) and Zhu Haorong (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
